19/12/2022 GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
The Ministry of Health’s Drug Advisory Committee has recommended:
Dulaglutide 0.75 mg and 1.5 mg solution for injection in pre-filled pen for treating type 2 diabetes mellitus:
- as a triple therapy in combination with two oral anti-diabetic drug (OAD) therapies for patients with inadequate glycaemic control despite treatment with optimal doses of dual OAD therapy, or as a dual therapy in combination with one OAD therapy if a dual OAD therapy is contraindicated or not tolerated; and
- in combination with insulin and metformin, unless metformin is contraindicated or not tolerated.
Funding status
RDulaglutide 0.75 mg and 1.5 mg solution for injection in pre-filled pen is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 February 2023.
NRMAF assistance does not apply to any formulations or strengths of liraglutide or semaglutide for treating type 2 diabetes mellitus.